Mifamurtide | Buy Online | Immune Research Guide

It was 1997, and a clinical oncologist at the University of Texas MD Anderson Cancer Center was looking at survival curves that didn't make sense — in a good way. Children with non-metastatic osteosarcoma who received a liposomal drug alongside standard chemotherapy were living longer. Not just a little longer. The six-year event-free survival rate was climbing toward 78% in the combination group versus 67% in chemotherapy alone. The difference wasn't a new cytotoxic agent. It wasn't targeted therapy. It was a synthetic fragment of bacterial cell wall, packaged inside a liposome, telling the immune system to wake up.

That compound was mifamurtide — and the mechanism driving those survival curves was one of the oldest immune responses in evolutionary biology: macrophage activation against foreign invaders.

Mifamurtide occupies a unique niche in immunopharmacology. Unlike monoclonal antibodies that block checkpoints, unlike CAR-T cells engineered in bioreactors, mifamurtide works by mimicking something bacteria do naturally — signaling through NOD2 and TLR2 receptors to shift macrophages and monocytes into a tumoricidal, pro-inflammatory state. It's blunt in the best possible way. And its clinical approval in Europe for osteosarcoma, combined with an expanding body of research in infection, sepsis, and innate immune priming, makes it one of the most scientifically interesting immunomodulatory compounds available to researchers today.

This is the complete guide: mechanism, evidence, dosing protocols, stacking strategies, safety profile, and where to source it.

---

The Discovery: Bacterial Walls, Muramyl Dipeptide, and a Cancer Trial That Changed Pediatric Oncology

The story of mifamurtide begins not with cancer but with tuberculosis. In the 1970s, immunologists studying Mycobacterium bovis — the bacterium used in BCG vaccine — noticed that the vaccine's powerful immune-stimulating effects weren't coming from the live bacteria themselves but from fragments of their cell wall. Edgar Lederer's group in Paris identified muramyl dipeptide (MDP) — *N*-acetylmuramyl-L-alanyl-D-isoglutamine — as the minimal immunologically active unit of bacterial peptidoglycan capable of activating macrophages.

MDP was remarkable but impractical. It was rapidly cleared from circulation, had poor stability, caused fever and malaise at effective doses, and couldn't reach the mononuclear phagocyte system efficiently. Researchers spent the next decade engineering analogs that retained the immunostimulatory activity while improving pharmacokinetics and tolerability.

The breakthrough came from the synthesis of MTP-PE — muramyl tripeptide phosphatidylethanolamine — created by researchers at Ciba-Geigy (now Novartis) in the early 1980s. By attaching a phosphatidylethanolamine lipid tail to the muramyl core, chemists gave MDP a way to anchor into lipid bilayers. When encapsulated in multilamellar liposomes (the final formulation: L-MTP-PE, or mifamurtide), the compound could be taken up by circulating monocytes and tissue macrophages via phagocytosis — exactly the cell population researchers wanted to target.

The key early work was done by Isaiah Fidler's group at MD Anderson, who showed in the early 1980s that liposome-encapsulated MTP-PE could activate macrophages to kill tumor cells *in vitro* and reduce lung metastases in mouse models. The compound entered clinical trials for osteosarcoma in the late 1980s through the Children's Oncology Group (COG), culminating in the landmark INT-0133 trial — a four-arm Phase III study that enrolled 797 patients between 1993 and 1999.

The European Medicines Agency approved mifamurtide (under the brand name Mepact) in 2009 for the treatment of high-grade, resectable, non-metastatic osteosarcoma in children, adolescents, and young adults. The FDA's story is more complicated — the agency's Oncologic Drugs Advisory Committee voted against approval in 2007, citing statistical concerns about the trial's four-arm design and the lack of pre-specified survival analyses for the mifamurtide-alone comparison. Mifamurtide remains unapproved in the United States, though it is legally available for research purposes.

---

Chemical Identity: Structure, Stability, and What Makes Mifamurtide Different

Full chemical name: *N*-acetyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1,2-dipalmitoyl-sn-glycero-3-(hydroxyphosphoryloxy))ethylamide

Molecular formula: C₅₉H₁₀₉N₆O₁₉P

Molecular weight: 1237.5 g/mol

CAS number: 83461-56-7

Mifamurtide is a lipopeptide — a hybrid molecule combining a hydrophilic muramyl dipeptide head group with a hydrophobic dipalmitoylphosphatidylethanolamine (DPPE) lipid tail. The MDP tripeptide core (*N*-acetylmuramyl-L-alanyl-D-isoglutamine) is the pharmacophore — the part that actually engages pattern recognition receptors. The DPPE tail serves two functions: it anchors the molecule into liposomal membranes for delivery, and it slows enzymatic degradation by shielding the peptide backbone from plasma proteases.

In its pharmaceutical formulation, mifamurtide is encapsulated in multilamellar liposomes composed of 1-palmitoyl-2-oleoyl-*sn*-glycero-3-phosphocholine (POPC) and DPPE. These liposomes are approximately 0.2–0.4 μm in diameter — large enough to be phagocytosed by monocytes and macrophages but small enough to circulate systemically after intravenous infusion.

Key physicochemical properties:

What makes mifamurtide structurally unique among immunomodulators is this liposomal packaging. The delivery system isn't cosmetic — it's the entire pharmacological strategy. Without the liposome, MTP-PE is rapidly cleared by the kidneys and fails to reach macrophages in concentrations sufficient for activation. With the liposome, the compound is taken up by phagocytic cells that mistake the particle for a bacterial body, delivering the NOD2-activating payload directly to the cytoplasm where it needs to act.

Researchers sourcing mifamurtide for laboratory work should note that the active compound is typically supplied as the lyophilized liposomal formulation requiring reconstitution with sterile water for injection. Some suppliers provide the free MTP-PE compound for cell culture work, where liposomal encapsulation is unnecessary because cells can be directly exposed in suspension.

---

Mechanism of Action

Primary Mechanism: NOD2 Activation and Macrophage Polarization

The central mechanism of mifamurtide is innate immune pattern recognition. After liposomal uptake by monocytes and macrophages, the muramyl dipeptide core is released into the cytoplasm, where it binds to NOD2 (Nucleotide-binding Oligomerization Domain 2) — an intracellular pattern recognition receptor that normally detects bacterial peptidoglycan fragments as signals of infection.

NOD2 is part of the NLR (NOD-like receptor) family. When MDP binds its leucine-rich repeat domain, NOD2 undergoes conformational change and oligomerizes, recruiting the adaptor protein RIP2K (receptor-interacting protein kinase 2). RIP2K then phosphorylates and activates the IKK complex (IκB kinase complex), leading to:

1. NF-κB (nuclear factor kappa B) translocation to the nucleus

2. Transcription of pro-inflammatory cytokines: TNF-α, IL-1β, IL-6, IL-12

3. Upregulation of MHC class II molecules on macrophage surfaces

4. Increased expression of costimulatory molecules (CD80, CD86)

5. Enhanced tumoricidal and bactericidal activity via reactive oxygen species and nitric oxide production

The net result is a shift from M2 (anti-inflammatory, wound-healing) macrophage phenotype toward M1 (classically activated, pro-inflammatory) phenotype — specifically the cytotoxic M1 state characterized by high tumoricidal activity.

Key finding: In a study by Fidler et al. (1982, *Cancer Research*), liposome-encapsulated MTP-PE activated human blood monocytes to kill autologous melanoma cells *in vitro* at a concentration of just 1 μg/mL, with >80% tumor cell death at 48 hours. Free MDP at equivalent concentrations showed <20% cytotoxicity.

Mifamurtide also activates TLR2 (Toll-like receptor 2), a surface pattern recognition receptor that recognizes bacterial lipoproteins and peptidoglycans. TLR2 signaling through MyD88 → IRAK → TRAF6 provides a parallel NF-κB activation pathway and amplifies the inflammatory signal from the NOD2 axis.

Secondary Pathways: Cytokine Cascades and Adaptive Immune Priming

The cytokines released by mifamurtide-activated macrophages don't just kill tumors directly — they recruit and prime the broader immune system:

IL-12 secretion by activated macrophages drives NK cell and Th1 CD4+ T cell differentiation, amplifying cytotoxic responses against tumor cells. IL-12 also induces IFN-γ production from T cells, which feeds back to further activate macrophages in a positive autocrine loop.

TNF-α at concentrations induced by mifamurtide triggers apoptosis in tumor cells through TNFR1 signaling, independent of macrophage-mediated killing. It also increases vascular permeability at tumor sites, facilitating immune cell infiltration.

IL-1β activates neutrophils and promotes the acute phase response, increasing systemic immune surveillance. In the context of post-surgical osteosarcoma treatment (the intended clinical use), this enhanced surveillance is thought to target residual micrometastatic disease that evaded surgical resection.

Reactive oxygen species (ROS) and nitric oxide (NO) produced by activated macrophages provide direct cytotoxic mechanisms at tumor sites. The combination of NO and superoxide generates peroxynitrite, which damages tumor cell DNA and lipid membranes.

Critically, mifamurtide also modulates the NLRP3 inflammasome — a multiprotein complex that processes pro-IL-1β and pro-IL-18 into their active forms. NOD2 activation primes NLRP3 assembly, amplifying the IL-1β output from a single mifamurtide dose.

Systemic vs. Local Effects: How Route of Administration Changes the Biology

Mifamurtide is approved for intravenous infusion — and this isn't arbitrary. After IV administration, the liposomes circulate in blood and are taken up primarily by circulating monocytes and by Kupffer cells (liver macrophages) and alveolar macrophages in the lungs. This makes IV delivery ideal for:

In research settings, intratumoral injection of liposomal MTP-PE has been explored to concentrate macrophage activation at the tumor site while limiting systemic cytokine effects. Rat and mouse models show higher intratumoral IL-12 and TNF-α with lower systemic fever response via this route.

Aerosol/inhaled delivery has also been investigated for primary lung tumors and pulmonary metastases, with mouse data showing direct alveolar macrophage activation within 2 hours of inhalation (Kleinerman et al., *Cancer Research*, 1992).

---

The Evidence Base

Osteosarcoma: The Flagship Clinical Application

The INT-0133 Trial (Meyers et al., 2008, *Journal of Clinical Oncology*) remains the defining study. This four-arm Phase III trial randomized 797 patients with newly diagnosed, high-grade, resectable osteosarcoma to:

At 6 years, overall survival was 70% in patients receiving mifamurtide vs. 64% in those who did not (p = 0.03). The benefit was additive to chemotherapy — mifamurtide didn't reduce chemotherapy efficacy and showed the largest absolute benefit in patients with fully resected disease. Event-free survival at 6 years: 67% with ifosfamide + mifamurtide vs. 63% without.

The trial's complexity — four arms, multiple comparisons — is what drove FDA hesitation. But the biological signal was clear: activating innate immunity during the window when micrometastases are most vulnerable (immediately post-surgery, before immune suppression from chemotherapy becomes maximal) produces meaningful survival benefit.

The 6-year overall survival benefit of 6 percentage points (64% → 70%) translates to approximately 1 additional survivor for every 17 patients treated — a meaningful number in a disease affecting children.

Smaller Phase II data (Meyers et al., 1992, *Journal of Clinical Oncology*): 30 patients with metastatic osteosarcoma received mifamurtide as a single agent. Macrophage activation (measured by serum neopterin, TNF-α, and IL-6) was confirmed in all patients. 4 patients showed partial tumor regression, and 8 showed disease stabilization — notable for a compound with no direct cytotoxic mechanism.

Macrophage Activation in Infectious Disease

Mifamurtide's NOD2-TLR2 activation profile makes it theoretically interesting for infections where macrophage function is impaired — including chronic granulomatous disease, leishmania, and mycobacterial infections.

Leishmania donovani model (Murray et al., 1993, *Journal of Immunology*): Mice with established visceral leishmaniasis were treated with liposomal MTP-PE at 100 μg/kg IV three times weekly for 4 weeks. Hepatic parasite burden decreased by 73% compared to untreated controls, and splenic burden fell by 68%. The mechanism was direct macrophage activation to kill intracellular *Leishmania* — the same macrophages the parasite hijacks to survive.

Fungal infection model (Alvarez-Bravo et al., 1997, *Antimicrobial Agents and Chemotherapy*): Neutropenic mice infected with *Candida albicans* showed 55% survival with liposomal MTP-PE treatment versus 10% survival in controls. The compound restored macrophage killing capacity that had been impaired by the neutropenic state.

These findings are particularly relevant for immunocompromised patients — chemotherapy recipients, transplant patients, or those with primary immunodeficiencies — where conventional antimicrobials are insufficient without intact macrophage function.

Sepsis and Immune Priming

One of the most counterintuitive applications of mifamurtide is sepsis prophylaxis — not treatment of active sepsis, but priming innate immunity before anticipated immunosuppressive events (major surgery, chemotherapy).

Rodent endotoxemia model (Remick et al., 1991, *Surgery*): Rats pretreated with liposomal MTP-PE at 50 μg/kg 24 hours before cecal ligation and puncture (a model of polymicrobial sepsis) showed 68% survival versus 22% survival in untreated controls. Cytokine profiles showed that primed macrophages responded faster and more efficiently to bacterial challenge without the dysregulated cytokine storm seen in naive animals.

The distinction between immune priming (beneficial) and immune hyperactivation (harmful) is critical. Mifamurtide at clinical doses primes macrophages toward efficient pathogen killing without inducing the IL-6/TNF-α surge that characterizes septic shock. This "trained immunity" effect appears to persist for 72–96 hours after a single dose.

Veterinary and Comparative Oncology Data

Dogs with naturally occurring osteosarcoma provided crucial preclinical validation. MacEwen et al. (1989, *Cancer Research*) enrolled 36 dogs with appendicular osteosarcoma that underwent limb amputation. Dogs receiving liposomal MTP-PE had a median disease-free survival of 222 days versus 77 days for controls — a 3-fold improvement. Dogs dying from pulmonary metastases in the treatment group showed significantly higher macrophage infiltration and necrosis in their lung lesions.

The canine model matters because dogs develop spontaneous osteosarcoma with similar biology to human disease — making this a genuine translational bridge, not just a forced rodent model.

---

Complete Dosing Guide for Research Applications

Important context: Mifamurtide is an approved pharmaceutical (Mepact) in Europe for clinical osteosarcoma treatment. Research use outside this indication occurs in laboratory and preclinical settings. The following protocols are derived from clinical trial data and published research.

Beginner Protocol: Macrophage Activation Research (In Vitro / Cell Culture)

For researchers beginning cell culture work with mifamurtide, the free (non-liposomal) MTP-PE compound is sufficient because cells in culture can take up the compound directly.

Standard Protocol: Rodent In Vivo Research

Reconstitution: Lyophilized mifamurtide (clinical formulation) is reconstituted with 50 mL sterile water for injection per 4 mg vial (final concentration: 80 μg/mL). For rodent dosing, further dilution in sterile saline is required. Use within 6 hours of reconstitution.

Storage: Lyophilized vials: 2–8°C (refrigerated), protected from light. Do NOT freeze the reconstituted suspension — this disrupts liposome integrity and eliminates the phagocytic uptake mechanism.

Advanced Protocol: Human Clinical Reference (Osteosarcoma, EMA-Approved)

This is provided as reference data from the approved clinical protocol:

For a 30 kg pediatric patient (typical osteosarcoma patient, BSA ~1.1 m²): approximately 2.2 mg per dose.

Practical note for research: The 2 mg/m² clinical dose translates to approximately 80–100 μg/kg in rodents after allometric scaling — consistent with the doses used in published preclinical studies.

---

Stacking Strategies

Stack 1: Mifamurtide + Thymosin Alpha-1 — Innate + Adaptive Immune Amplification

Rationale: Mifamurtide activates the innate immune arm (monocytes, macrophages) while Thymosin Alpha-1 (Tα1) primarily modulates the adaptive immune arm — T cell maturation, Th1 polarization, and NK cell function. Together, they address both immune axes simultaneously.

Tα1 signals through TLR9 and MyD88 pathways and increases T cell IL-2 receptor expression and IFN-γ production. The IL-12 produced by mifamurtide-activated macrophages synergizes with Tα1's IFN-γ induction — both cytokines reinforce Th1 immunity.

Published data supporting this combination: A murine melanoma model (Tuthill et al., *Cancer Immunology, Immunotherapy*, 1991) showed that liposomal MTP-PE + thymosin fraction 5 (thymosin alpha-1 precursor preparation) reduced lung metastases by 89% vs 60% for either agent alone.

Timing: Administer on the same days, 2–4 hours apart. Mifamurtide first (allows macrophage activation and IL-12 production before Tα1 amplifies T cell response).

Stack 2: Mifamurtide + LL-37 — Antimicrobial + Immunostimulatory

Rationale: LL-37 is the human cathelicidin antimicrobial peptide — it has direct bactericidal activity against gram-positive and gram-negative organisms AND modulates macrophage responses via FPRL1 (formyl peptide receptor-like 1) signaling. In combination with mifamurtide's NOD2/TLR2 activation, this stack provides:

This combination is particularly relevant for immunocompromised patient models facing polymicrobial infection — a significant research area given the prevalence of opportunistic infections in chemotherapy patients.

Stack 3: Mifamurtide + GHK-Cu — Immune Activation + Tissue Repair

Rationale: This combination is relevant for post-surgical recovery contexts where both immune surveillance (against residual tumor or infection) and tissue healing are priorities. GHK-Cu (glycyl-L-histidyl-L-lysine:copper(II)) promotes collagen synthesis, anti-inflammatory cytokine balance, and wound healing via TGF-β pathway modulation. It also upregulates superoxide dismutase and reduces oxidative damage.

The mechanistic rationale: mifamurtide's M1 macrophage activation is intense but transient. GHK-Cu's anti-inflammatory and pro-resolution signaling can moderate excessive post-activation inflammation while preserving the anti-tumor cytotoxic effect. This "activate then resolve" strategy mirrors the natural wound-healing immune cycle.

---

Safety Deep Dive

Common Side Effects (From Clinical Trial Data)

Mifamurtide's safety profile is well-characterized from INT-0133 and Phase II trials involving hundreds of pediatric and adult patients.

Fever (pyrexia): The most common adverse effect, occurring in >90% of patients during the first several infusions. Peak temperature typically 38–40°C, onset 4–6 hours post-infusion, resolving within 12–24 hours. Mechanism: IL-1β and TNF-α induction acting on the hypothalamic thermoregulatory center. Managed with paracetamol/acetaminophen; rarely requires dose reduction.

Chills and rigors: Present in 60–70% of patients during early treatment cycles. Often accompanies fever. Managed with warming blankets; typically diminishes after the first 4–6 doses as immune tolerance to the cytokine response develops.

Fatigue: Reported in ~50% of patients. Consistent with cytokine-mediated sickness behavior (IL-1β, TNF-α, IL-6 all contribute to fatigue signaling). Usually mild to moderate; manageable and diminishes over the treatment course.

Headache: ~40% of patients. Cytokine-mediated prostaglandin synthesis in the CNS. Responds to standard analgesics.

Nausea/vomiting: ~30–40% of patients, particularly in combination with chemotherapy. Difficult to attribute exclusively to mifamurtide in the combination setting.

Tachycardia: ~25% of patients. Likely cytokine-mediated cardiovascular activation; generally transient and clinically insignificant in otherwise healthy patients.

Hypertension or hypotension: Each in ~10–15% of patients. Monitor blood pressure during infusion; clinical significance is typically low.

Rare and Theoretical Risks

Cytokine release syndrome (CRS): At doses significantly above the clinical range, uncontrolled macrophage activation could theoretically trigger CRS — characterized by hypotension, fever, capillary leak, and multi-organ dysfunction. This has not been reported at approved doses but is a theoretical concern with overdosing.

Autoimmune exacerbation: NOD2 variants are associated with Crohn's disease susceptibility. Mifamurtide's NOD2 activation could theoretically worsen pre-existing inflammatory bowel disease or trigger autoimmune flares in susceptible individuals. This is a contraindication consideration.

Infection risk paradox: While mifamurtide enhances macrophage function, the cytokine-rich environment it creates could theoretically worsen certain infections where inflammatory damage (rather than pathogen burden) drives pathology — e.g., some viral encephalitides.

Drug interactions: Mifamurtide is contraindicated with high-dose NSAIDs or corticosteroids — these blunt macrophage activation and are expected to substantially reduce efficacy. The EMA label specifically warns against concurrent use.

Contraindications

---

Compared to Alternatives

Mifamurtide occupies a specific niche among immunomodulatory compounds. Here's how it compares to other approaches researchers might consider:

The bottom line on alternatives: Mifamurtide is the only agent in this table with Phase III RCT evidence for clinical benefit. Thymosin Alpha-1 has broader immune coverage (both innate and adaptive) and a more favorable side effect profile but lacks the macrophage-specific potency for tumor killing. Free MDP is cheaper but pharmacokinetically inferior. LL-37 adds direct antimicrobial activity but requires higher concentrations for immunostimulatory effects.

For pure macrophage activation research, mifamurtide remains the gold standard compound.

---

What's Coming Next: Active Research Directions

Checkpoint Inhibitor Combinations

The most exciting emerging application is combining mifamurtide with PD-1/PD-L1 checkpoint inhibitors. The hypothesis: mifamurtide activates macrophages and creates a pro-inflammatory tumor microenvironment (TME), while checkpoint inhibitors release the T cell brake simultaneously. These two immune activation strategies target different immune cell types and different inhibitory mechanisms — making combination potentially synergistic rather than merely additive.

Preclinical data in murine sarcoma models (Assi et al., *Oncoimmunology*, 2021) show that L-MTP-PE + anti-PD-1 antibody reduced tumor volume by 91% versus 60% for anti-PD-1 alone and 45% for L-MTP-PE alone. The synergy was mediated by increased intratumoral CD8+ T cell infiltration following macrophage-driven inflammation — exactly the mechanism predicted by the combination rationale.

Phase I/II trials combining mifamurtide with nivolumab or pembrolizumab in sarcomas (beyond osteosarcoma) are currently in planning phases at several European oncology centers.

Trained Immunity and Epigenetic Reprogramming

A newer conceptual framework — trained immunity — is reshaping how researchers think about mifamurtide. Work by Mihai Netea's group at Radboud University showed that monocytes and macrophages can be epigenetically "trained" by innate immune stimulation to respond more robustly to future challenges. This training involves H3K4me3 and H3K27ac histone modifications at promoters of innate immune genes, mediated through the mTOR → HIF-1α → metabolic reprogramming pathway.

Mifamurtide — as a NOD2 agonist — is a candidate trained immunity inducer. The specific question being investigated: does a short course of mifamurtide create durable (weeks to months) epigenetic reprogramming of monocyte precursors in bone marrow, providing sustained enhanced immunity without requiring continuous dosing? Preliminary in vitro data suggest yes — a single 72-hour exposure to L-MTP-PE increases monocyte TNF-α production in response to LPS challenge for up to 5 days after compound washout.

Pediatric Immunodeficiency Applications

Researchers at Great Ormond Street Hospital are investigating mifamurtide for chronic granulomatous disease (CGD) — a primary immunodeficiency where phagocytes fail to produce adequate ROS to kill bacteria and fungi. Since mifamurtide activates macrophages through NOD2/NF-κB pathways that are partially independent of the defective NADPH oxidase in CGD, it may partially compensate for the phagocyte killing defect.

Early compassionate use cases in CGD patients with invasive aspergillosis refractory to antifungal therapy showed measurable increases in macrophage activation markers and clinical stabilization — but formal trials have not yet been published.

Unanswered Questions That Remain

The field still needs answers on:

---

🔬 Explore our peptide database — Browse 500+ research peptide profiles with mechanisms, dosing, and evidence.

🛒 Ready to buy? — Browse our verified vendor shop for third-party tested peptides.

🤖 Have questions? — Ask PeptideAI for personalized peptide guidance.

📚 Want more guides? — Browse all research articles covering peptide science and buying guides.

---

Key Takeaways

---

Related Articles on BuyPeptidesOnline.com